Abstract:The WHO recommends dolutegravir as part of first-line antiretroviral therapy (ART) for persons living with HIV [1]. Consequently, pregnant women living with HIV (WLHIV) are increasingly receiving dolutegravir-based ART worldwide. Although some studies have reported on birth outcomes in this population [2], there are no data on fetal biometry in pregnant WLHIV receiving dolutegravir. We assessed the association of dolutegravir-based or efavirenz-based ART with fetal biometry, using a comparison group of HIV/ART-unexposed fetuses. We enrolled pregnant WLHIV and pregnant women without HIV between 16 and 36 weeks gestation in the Tshilo Dikotla cohort in Botswana from August 2016 to May 2019. WLHIV received tenofovir and emtricitabine and either dolutegravir (dolutegravir-based ART) or efavirenz (efavirenz-based ART) during pregnancy. Pregnancies with multiple gestations or ending in fetal demise were excluded. The study was approved by the Human Research and Development Committee in Botswana and the Institutional Review Boards at Northwestern University Feinberg School of Medicine and the Ann and Robert H. Lurie Children's Hospital of Chicago. Head circumference, biparietal diameter, abdominal circumference, and femoral length Z scores from a single ultrasound performed in the second trimester were calculated using INTERGROWTH-21st standards [3]. Linear regression models were fit to assess the association of in-utero HIV/ART exposure with each fetal biometric Z score. Of the 469 pregnant women enrolled, 182 received dolutegravir-based ART, 127 efavirenz-based ART, and 160 were without HIV. WLHIV on efavirenz-based ART were oldest, followed by those on dolutegravir-based ART and those without HIV (median age 32 vs. 28 vs. 24 years, respectively, P < 0.01), highest in parity (3 vs. 2 vs. 1, respectively, P < 0.01), and least likely to have completed tertiary education (7.9% vs. 14.3% vs. 33.1%, respectively, P < 0.01). Gestational age at ultrasound was higher in WLHIV than women without HIV (28 vs. 26 weeks, P < 0.01). Viral load and CD4 values were similar between WLHIV on dolutegravir-based vs. efavirenz-based ART (Table 1). Table 1 - Fetal biometry and neonatal anthropometric Z scores by in-utero HIV/antiretroviral therapy exposure status. In-utero exposure to HIV and TDF/FTC/DTG In-utero exposure to HIV and TDF/FTC/EFV HIV/ART-unexposed P value Fetuses n = 182 n = 127 n = 160 HC –0.4 (–1.0, 0.3) –0.5 (–1.1, 0.0) –0.3 (–0.9, 0.4) 0.060 BPD 0.1 (–0.6, 0.8) –0.0 (–0.7, 0.7) 0.1 (–0.6, 0.7) 0.464 AC 0.3 (–0.4–0.7) 0.5 (–0.2–1.0) 0.1 (–0.5–0.8) 0.172 FL 1.5 (0.7–2.0) 1.5 (0.8–2.1) 1.3 (0.5–2.1) 0.396 Estimated FW 0.6 (0.2–0.9) 0.7 (0.4–1.0) 0.5 (0.0–1.0) 0.347 Neonates n = 166 n = 144 n = 131 BW –0.2 (–0.9, 0.6) –0.1 (–0.9, 0.7) –0.1 (–0.8, 0.5) 0.575 BL 1.1 (0.0, 2.1) 1.2 (0.0, 2.0) 1.3 (–0.0, 2.4) 0.458 BHC –0.4 (–1.0, 0.3) –0.5 (–1.1, 0.0) –0.3 (–0.9, 0.4) 0.060 AC, abdominal circumference; ART, antiretroviral therapy; BHC, birth head circumference; BL, birth length; BPD, biparietal diameter; BW, birth weight; DTG, dolutegravir; FL, fetal length; FTC, emtricitabine; FW, fetal weight; HC, head circumference; TDF, tenofovir. In unadjusted analyses, overall, Z scores for all fetal biometry measurements did not differ significantly between groups (Table 1). Findings persisted after adjusting for maternal age, height, education level, parity and alcohol use in pregnancy. Birth anthropometrics were available for 94% of infants and were similar between groups. In this cohort in Botswana, there were no differences in fetal biometry between fetuses exposed to dolutegravir-based ART, those exposed to efavirenz-based ART, and those unexposed to HIV/ART. This is the first study to evaluate fetal biometric measurements in pregnant WLHIV receiving dolutegravir. Fetal ultrasound including fetal biometry is an important tool for measuring fetal well being, anomalies, and growth, allowing early detection and subsequent management of potential in-utero conditions which may place the fetus or mother at risk for poor outcomes at birth/delivery [4]. Though our study was limited by its single site study design, small sample size, and the lack of longitudinal ultrasonography, these results appear reassuring and support the continued use of dolutegravir-based regimens in pregnancy. Larger studies with serial ultrasonography are needed to validate these findings. Acknowledgements F.M.B. drafted the first version of the article. K.M.P. and J.J. conceptualized the study. S.S. performed the data analysis. F.M.B., K.M.P., S.S., J.M., G.M., L.M.Y., and J.J. reviewed the article, whereas K.M.P., L.M.Y., and J.J. gave substantive feedback on the final version. The study was funded by the National Institute of Diabetes and Digestive and Kidney Disease (NIDDK) (R01DK109881). Conflicts of interest The authors have no financial conflicts of interest to disclose.

Development of normal reference intervals for renal function in pregnancy: a secondary analysis of clinical trial data

Safety of Efavirenz in First-trimester of Pregnancy

Reference Intervals for Common Renal and Liver Function Clinical Chemistry Parameters Among Apparently Healthy Pregnant and Non-pregnant Women in South Wollo Zone, Amhara National Regional State, Northeast Ethiopia

Cardiometabolic health in pregnancy and postpartum: Findings form a prospective cohort study in South Africa

Changes in estimated glomerular filtration rate over time in South African HIV-1-infected patients receiving tenofovir: a retrospective cohort study

Evaluation of pharmacokinetics of Tenofovir Alafenamide (TAF) and Tenofovir Disoproxil (TDF) in pregnant and postpartum women in South Africa: PrEP-PP PK study

Lipid and glucose profiles in pregnant women with HIV on tenofovir-based antiretroviral therapy

Markers of Maternal Bone and Renal Toxicity Through 50 Weeks Postpartum: IMPAACT 2010 (VESTED) Trial

Maternal kidney function during pregnancy: systematic review and meta‐analysis

In‐utero exposure to tenofovir‐containing pre‐exposure prophylaxis and bone mineral content in HIV‐unexposed infants in South Africa

Assessment of the impact of HIV infection and anti-retroviral treatment on the cardiometabolic health of pregnant mothers and their offspring (ARTMOMSBABES)

Determinants of early change in serum creatinine after initiation of dolutegravir‐based antiretroviral therapy in South Africa

Pregnancy outcomes for women with pre‐existing renal disease and the role of a dedicated joint maternal medicine and renal clinic: A retrospective cohort study

Fetal Biometry Following In-Utero Exposure to Dolutegravir-Based or Efavirenz-Based Antiretroviral Therapy

Hypertensive disorders of pregnancy and HIV: analysis of a province-wide cohort during 2018 and 2019

A systematic review assessing the potential use of cystatin c as a biomarker for kidney disease in people living with HIV on antiretroviral therapy

Development of a formula for estimated glomerular filtration rate in pregnant women from physiological hyperfiltration of serum creatinine

Effects of the timing of maternal antiretroviral therapy initiation, CD4 count, and HIV viral load on birth outcomes in the Eastern Cape province of South Africa: A secondary data analysis

Significant kidney disease in pregnancy: Feasibility and outcomes of a national population‐based study using the Australasian Maternity Outcomes Surveillance System

First and second trimester markers of fetal aneuploidy in pregnant women with HIV infection

Pregnancy and Glomerular Disease: A Systematic Review of the Literature with Management Guidelines